Straight From the Cutter's Mouth
    CME 0.5 General AMA PRA Category 1 Credits™

    Dr. Daniel Chao and Dr. Shriji Patel join to discuss 3 recent articles in JAMA Ophthalmology regarding drug prices in the US and Australia, SCORE2 secondary analysis results and statins for diabetic retinopathy.

    Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alimera, Alcon and Allergan. Dr. Chao is a consultant for Recens Medical Inc., DTXPharma, Allergan, Visgenx and Zilia, and receives research funding from the National Eye Institute, Bright Focus Foundation, Clearside Biomedical Inc., Chengdu Pharmaceuticals, Opthea Ltd, Genentech and Apellis Pharmaceuticals.

    CME Information

    Release: Feb. 4, 2019; expires Feb. 4, 2022

    Reviewers: Purnima Patel, MD; Shriji Patel, MD; Carl Danzig, MD

    Disclosures: The physician reviewers and Academy staff report no relevant financial disclosures.

    Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards of care for the management of vitreoretinal disorders or the outcomes from recent research and how these impact patient care decisions.

    Audience: This activity is intended for retina subspecialists and comprehensive ophthalmologists.

    Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    The American Academy of Ophthalmology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits.
    TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.